METHOD FOR PREPARING HETEROGENEOUS HEMATOPOIETIC STEM AND PROGENITOR CELLS USING NON-MOBILIZED PERIPHERAL BLOOD
20200224166 ยท 2020-07-16
Inventors
Cpc classification
C12N2501/125
CHEMISTRY; METALLURGY
C12N2501/165
CHEMISTRY; METALLURGY
A61K49/0008
HUMAN NECESSITIES
C12N2500/90
CHEMISTRY; METALLURGY
C12N5/0647
CHEMISTRY; METALLURGY
C12N2501/999
CHEMISTRY; METALLURGY
C12N15/1096
CHEMISTRY; METALLURGY
C12Q1/6876
CHEMISTRY; METALLURGY
International classification
C12N15/10
CHEMISTRY; METALLURGY
C12Q1/6806
CHEMISTRY; METALLURGY
C12Q1/6876
CHEMISTRY; METALLURGY
Abstract
The present disclosure provides a method for preparing heterogeneous hematopoietic stem and progenitor cells using non-mobilized peripheral blood, which uses a capsule culture system to capture and proliferate rare hematopoietic stem and progenitor cells in non-mobilized peripheral blood, and prepares heterogeneous hematopoietic stem and progenitor cell clones. The present disclosure captures the rare heterogeneous stem cells in non-mobilized peripheral blood and morphologically verifies the presence of heterogeneous hematopoietic stem and progenitor cells in non-mobilized peripheral blood. The method of the present disclosure has the characteristics of hematopoietic reconstitution, drug development, transplantation and immunotherapy, gene editing of cell types, and the like. The method of the present disclosure provides a reliable cell source for patient-specific functional hematopoietic stem cells, and actively promotes the clinical application of non-mobilized hematopoietic stem and progenitor cells.
Claims
1. A method for preparing heterogeneous hematopoietic stem and progenitor cells using non-mobilized peripheral blood, the method comprising the following steps: (1) source and preparation of initiating cells using normal peripheral blood without mobilizing drug treatment to obtain a blood product, removing erythrocytes from the obtained blood product by using a lymphocyte separation solution or an erythrocyte lysing solution, and washing the obtained mononuclear cells 2 to 3 times with a calcium ion and magnesium ion-free phosphate buffer solution to be ready for use as a source of cells to be initially cultured; (2) preparation and culture of heterogeneous hematopoietic stem and progenitor cell clones capsuling the above obtained mononuclear cells with hydrogel as a cell culture material and obtaining a capsule culture system, wherein, the cells are washed once with a 10% sucrose solution, re-suspended with 20% sucrose, capsuled with hydrogel, seeded in a well plate, and cultured in a culture medium, the culture medium being replaced every 2 to 3 days, so that clones with different morphologies appear; (3) detection of heterogeneity of hematopoietic stem and progenitor cell clones by single cell sequencing selecting single cell in the clones according to morphological characteristics, performing single cell sequencing, extracting single-cell RNAs, enriching eukaryotic mRNAs with magnetic beads with Oligo, synthesizing cDNAs using fragmented mRNAs as templates, purifying and recovering the obtained cDNAs by a kit, constructing a library by PCR amplification, sequencing the constructed library, detecting transcription expression of single-cell sequencing, analyzing gene expression, optimization of genetic structure, alternative splicing, prediction and annotation of new transcripts, and SNP detection according to a number of reads obtained by gene sequencing, and screening out genes that are differentially expressed among samples from gene expression results; (4) surface molecule expression of heterogeneous hematopoietic stem and progenitor cell clones growing various clones in the capsule culture system until each clone contains 30 to 80 cells, dispersing and mixing the system, performing digestion with an ethylenediamine tetraacetic acid digestive solution, passing the digested product through a 70 um mesh sieve, performing centrifugation to harvest cells, and detecting surface molecule expression of hematopoietic stem and progenitor cells in the harvested cells by using flow cytometry, including CD34, CD43, CD45, and CD90; (5) detection of in vitro differentiation potential selecting clones of several different morphologies appearing in the capsule culture system according to shapes of the clones, sorting 200 to 300 targeted cells for the clones, conducting a CFU experiment in a growth factor-containing methylcellulose semi-solid medium, and detecting multi-directional differentiation potential of different clones, including burst erythroid colonies, generally small erythroid colonies, granulocyte colonies, granulocyte-macrophage colonies, and erythroid-granulocyte-macrophage mixed cell colonies; (6) detection of growth potential of the cells in capsule culture system equally seeding non-mobilized peripheral blood mononuclear cells in capsule and non-capsule culture systems, conducting a growth potential study experiment in a medium containing a hematopoietic stem and progenitor cell growth factor, and detecting self-renewal potential of the different culture systems. (7) detection of expression of transcription factors of hematopoietic stem cells in capsule culture system studying biological characteristics of a whole cell population in the capsule cell culture system at a molecular level, detecting change of cells in the capsule culture system at a transcriptome level through RNA sequencing, especially hematopoietic stem cell-related transcription factors, signaling pathways, and microenvironment-related regulating factors; and (8) detection of in vivo hematopoietic differentiation potential of whole cell population in whole capsule cell culture system subjecting a cell population formed by dispersing various hematopoietic colonies to a transplantation experiment, detecting long-term in vivo self-renewal and multi-directional differentiation potential of the cells, and periodically detecting implantation of humanized cells in mice, where cells that are non-capsule cultured under the same conditions are used as a control.
2. The method for preparing the heterogeneous hematopoietic stem and progenitor cells using the non-mobilized peripheral blood according to claim 1, wherein in step (2), the culture medium consists of 20-150 ng/ml stem cell growth factor SCF, 20-150 ng/ml FMS-like tyrosine kinase 3 ligand antibody, 20-100 ng/ml thrombopoietin TPO, 10-50 ng/ml interleukin 6 IL6, 10-50 ng/ml interleukin 3 IL3, 2-10 ng/ml vascular growth factor VEGF, 10-20 ug/ml vitamin C, and puromycin derivative StemRegenin1.
3. The method for preparing the heterogeneous hematopoietic stem and progenitor cells using the non-mobilized peripheral blood according to claim 1, wherein in step (2), the clones of different morphologies appearing upon culturing comprises dense clones, vascular clones, paving stone-shaped clones, and freely dispersed clones.
4. The method for preparing the heterogeneous hematopoietic stem and progenitor cells using the non-mobilized peripheral blood according to claim 1, wherein in step (3), GO function significance enrichment analysis and pathway significance enrichment analysis are performed based on the genes that are differentially expressed to analyze cell clusters of principal components of single cells, so as to detect the heterogeneity of said various clones.
5. The method for preparing the heterogeneous hematopoietic stem and progenitor cells using the non-mobilized peripheral blood according to claim 1, wherein in step (7), the transcription factors comprise CD34, RUNX1, GATA2, c-MYC, HOXA9, HOXB4, GATA1, and TIE2; the signal pathways mainly comprise genes regulating self-renewal, multi-lineages potential and metabolism state; and the microenvironment-related regulating factors are mainly homing and cell adhesion-related genes.
Description
BRIEF DESCRIPTION OF DRAWINGS
[0020]
[0021]
[0022]
[0023]
[0024]
[0025]
[0026]
[0027]
[0028]
[0029]
[0030]
[0031]
[0032]
[0033]
[0034]
[0035]
[0036]
[0037]
[0038]
[0039]
[0040]
[0041]
DESCRIPTION OF EMBODIMENTS
[0042] The present disclosure is further described with reference to the accompanying drawings and examples. The materials, reagents, etc. used in the following examples are commercially available unless otherwise specified.
Example 1 Preparation of Heterogeneous Hematopoietic Stem and Progenitor Cell Clones by Using Non-Mobilized Peripheral Blood
[0043] It was briefly described as follows:
[0044] 1. The present invention provides a method for capturing rare stem cells in non-mobilized peripheral blood by using a capsule culture system, and preparing heterogeneous hematopoietic stem and progenitor cell clones. On the basis of obtaining the heterogeneous hematopoietic stem and progenitor cell clones, a large number of hematopoietic stem and progenitor cells can be obtained by using a small amount of non-mobilized peripheral blood, and can be continuously used for downstream molecule and cell biological function analysis. The specific scheme is shown in
2. Obtaining of Mononuclear Cells by Using Non-Mobilized Peripheral Blood
[0045] Volunteers were recruited. According to experimental needs, less than 1 ml or more than 1 ml of a blood product could be drawn aseptically and collected by using aseptic anticoagulation tubes.
[0046] 2.1 Lysing of Erythrocytes with Erythrocyte Lysing Solution
[0047] Erythrocytes were lysed by using an erythrocyte lysing solution, 2 to 4 ml of the lysing solution was added per 1 ml of non-mobilized peripheral blood to lyse for 5 to 8 min on ice, and the change in color of the blood product was observed; when the blood product changed from original deep red to pale red in color, and gradually changed from original opacity to transparency, a suitable amount of calcium ion and magnesium ion-free phosphate buffer solution was added for neutralization, mononuclear cells were obtained by centrifuging at 1500 rpm for 5 min, and washed 2-3 times with the calcium ion and magnesium ion-free phosphate buffer solution, and the obtained mononuclear cells were subjected to the next experiment.
[0048] 2.2 Separation of Mononuclear Cells from Blood Product by Using Lymphocyte Separation Solution
[0049] A lymphocyte separation solution and non-mobilized peripheral blood were added to a centrifuge tube according to a ratio of 1:2 to be centrifuged at 2500 rpm for 25 min at 4 C., a middle buffy coat was aspirated and washed 2-3 times with the calcium ion and magnesium ion-free phosphate buffer solution, and the obtained mononuclear cells were subjected to the next experiment.
3. Preparation of Heterogeneous Hematopoietic Stem and Progenitor Cell Clones
[0050] The mononuclear cells obtained from the non-mobilized peripheral blood were capsuled with a hydrogel with a moderate degree of softness and hardness, and the cells were enveloped in the material to be shaped like a capsule, which was called a capsule culture system. A serum-free hematopoietic stem cell proliferation medium SFEM (STEMCELL TECHNOLOGY) containing 20-200 ng/ml SCF, 20-200 ng/ml FLT3L, 10-20 ng/ml IL-3, 10-20 ng/ml IL-6, 10-100 ng/ml TPO, 2-10 ng/ml VEGF, and 5-30 ng/ml vitamin C was used for culturing, and the medium was replaced every 2 days. The growth statuses of cells and clones were observed under a microscope. The growth morphologies of clones and changes thereof were recorded. The morphological changes are shown in
4. Detection of Expression of Hematopoietic Stem and Progenitor Cell-Related Surface Markers in Capsule Culture System by Flow Cytometry
[0051] After the clones grew to a certain size, the cloned cells were dispersed, washed with a buffer solution, and the expression of hematopoietic stem and progenitor cell expressing markers in the capsule culture system was detected by flow cytometry.
[0052] The details were as follows:
[0053] After the clones in the capsule culture system grew to about 50-80 um, the whole system was gently pipetted with a pipette tip to decompose the capsule system, centrifuging was performed to collect cells, the cells were digested with 0.25% trypsin/ethylenediamine tetraacetic acid for 10 min, the digestion was terminated by using a bovine serum-containing medium, and the cells were gently pipetted, passed through a 70 um cell filter, and centrifuged at 1000 rpm for 5 min to collect the cells. The cells were washed 2-3 times with the calcium ion and magnesium ion-free phosphate buffer solution to be collected. The cell density was adjusted to 10.sup.6-10.sup.7 cells per milliliter, the cells were added with corresponding flow antibodies, including CD34, CD45, CD43, CD90, CD309, CD117, CD19, CD15, CD3, etc., incubated at room temperature in a dark place for 30 min, and washed 2-3 times with the phosphate buffer solution, the cells were re-suspended with 500 uL of a phosphate buffer solution (added with 1% FBS and 1 mM ethylenediamine tetraacetic acid), and expression of multiple hematopoietic cell surface antigens in the capsule culture system was detected by a BD FACScalibur instrument (Becton Dickinson). The isotype Ig was used as a control. Data was analyzed by a software FlowJo Version 7.2.5. The statistical analysis results of flow detection are shown in
5. Detection of In Vitro CFU Forming Potential of the Cells in Capsule Culture System
[0054] According to the morphologies of the clones, 200-300 CD34.sup.+ cells were sorted and cultured in a methylcellulose semi-solid medium containing a 20 ng/mL hematopoietic growth factor SCF, 20 ng/mL IL-3, 20 ng/mL IL-6, 20 ng/mL G-CSF, 20 ng/mL GM-CSF, 20 ng/mL TPO, and 3 U/mL EPO for about 2 weeks, and the formation of various hematopoietic CFU was detected. According to the morphological characteristics such as the structures formed by hematopoietic, cell size, color, and refractive index, the formation of various hematopoietic cell colonies was judged and counted. The results are shown in
6. Growth Potential Analysis of the Cells in Capsule Culture System
[0055] Non-mobilized peripheral blood mononuclear cells were cultured equally in capsule and non-capsule culture system with a serum-free hematopoietic stem cell proliferation medium SFEM (STEMCELL TECHNOLOGY) containing 20-200 ng/mL SCF, 20-200 ng/mL FLT3L, 10-20 ng/mL IL-3, 10-20 ng/mL IL-6, 10-100 ng/mL TPO, 2-10 ng/mL VEGF, and 5-30 ug/ml vitamin C, the medium was replaced every 2 days, the culture was performed for about 14 days, the cells were counted, and the proliferation of the cells was calculated. The detection of growth of cells in different culture systems is shown in
7. Detection of In Vivo Self-Renewal and Multi-Lineage Differentiation Potential of Cells Obtained in Capsule Culture System and Non-Capsule Culture System
[0056] The mononuclear cells in non-mobilized peripheral blood were cultured in the capsule culture system and the non-capsule culture system for about 2 weeks, and then transplanted to immunodeficient mice. The self-renewal and multi-lineage differentiation potential of the cells were estimated. The chimerism of human cells in mice was periodically detected, including peripheral blood, bone marrow, spleen, liver and other organs, the cell types include human T cells, B cells, and myeloid cells, and the T cells include Th1 and Th2 types. The detection results of in vivo self-renewal and multi-lineage differentiation abilities of capsule cultured and non-capsule cultured non-mobilized peripheral blood cells are shown in
8. Detection of Long-Term In Vivo Self-Renewal and Multi-Lineage Differentiation Potential of Cells Obtained in Capsule Culture System and Non-Capsule Culture System
[0057] The presence of human cells in the transplanted mice indicates that the transplanted cells in capsule culture system have the self-renewal and multi-lineage differentiation potential. After four months after the first transplantation, bone marrow cells were taken out for second transplantation to detect the long-term self-renewal and multi-lineage differentiation potential of the cells in capsule culture system. After 1 month, 2 months, 3 months and 4 months, the human cell content was detected, specifically including peripheral blood, bone marrow, spleen, liver and other organs, and the cell types include human T cells, B cells, and myeloid cells. The results are shown in
9. Detection of Regulatory Mechanism of Cells in Capsule Culture System at Molecular Level with Transcriptome Sequencing
[0058] The specific steps were as follows: after the total RNA was extracted from a sample and DNA was digested with DNase I, eukaryotic mRNA was enriched with magnetic beads with Oligo (dT), a fragmentation reagent was added to break the mRNA into short fragments in Thermomixer, the fragmented mRNA was used as a template to synthesize one-strand cDNA, and then a two-strand synthesis reaction system was prepared to synthesize two-strand cDNA, the two-strand cDNA was purified and recovered by a kit, the sticky end was repaired, a base A was added to the 3 terminal of cDNA and ligated with a linker, then the sizes of the fragments were selected, and finally PCR amplification was performed; after the constructed library passed a quality inspection by an Agilent 2100 Bioanalyzer and an ABI StepOnePlus Real-Time PCR System, the constructed library was then sequenced using an Illumina HiSeq 2000 sequencer.
[0059] Information analysis of data obtained by Illumina HiSeq 2000 sequencing was performed, and raw reads of raw data were subjected to quality control (QC) to determine whether the sequencing data was suitable for subsequent analysis or not. The clean reads obtained by filtering were aligned to a reference sequence. After the alignment was completed, it was judged whether the alignment results passed a QC of alignment by counting the alignment rate and the distribution of reads on the reference sequence, etc. If the alignment results passed the QC of alignment, a series of subsequent analysis including quantitative analysis of genes and transcripts, gene expression level-based analysis of various items (principal components, correlation, condition-specific expression, differential gene screening, etc.), exon quantification, optimization of gene structure, alternative splicing, prediction and annotation of new transcripts, SNP detection, Indel analysis, gene fusion, etc. was performed, and the screened differentially expressed genes among the samples were subjected to key transcription factor mining analysis. The results are shown in
[0060] 10. Detection of expression of key hematopoietic transcriptional regulatory factors in capsule cultured and non-capsule cultured non-mobilized peripheral blood cells by high-throughput fluorescent quantitative PCR. The primer sequence is shown in a typing sequence list. The results are shown in
11. Detection of Morphologies and Internal Structural Characteristics of Cells by Scanning and Transmission Electron Microscopy
[0061] The ultrastructures of cells were analyzed by a transmission electron microscopy (TEM). The samples were fixed with a 2.5% glutaraldehyde solution for more than 4 h. After being washed with the calcium ion and magnesium ion-free phosphate buffer solution, the samples were treated with 1% osmic acid for 1 h, and then washed 2-3 times with distilled water. After being fixed in 2% uranium acetate, the cells were dehydrated in ethanol having a series of concentrations of 50%, 70%, 90%, and 100% for 10-15 min each time, and finally, the cells were soaked twice in 100% acetone for 10-15 min each time. After infiltration, retention, polymerization, and staining with a lead uranyl acetate citric acid solution, the internal structures of the cells were observed by the transmission electron microscopy TEM (Tecnai Spirit) at low temperature. The results are shown in